Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

BACKGROUND: TP53 gene mutation is widely known as one of the determinants of impaired chemosensitivity. p53 is a tumor-suppressor protein in humans encoded by the TP53 gene. Some studies have shown that TP53 gene mutation and accumulation of the p53 protein are closely related with serum anti-p53 an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Cancer
Hauptverfasser: Osumi, Hiroki, Shinozaki, Eiji, Suenaga, Mitsukuni, Kumekawa, Yosuke, Ogura, Mariko, Ozaka, Masato, Matsusaka, Satoshi, Chin, Keisho, Yamamoto, Noriko, Mizunuma, Nobuyuki
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2015
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4618932/
https://ncbi.nlm.nih.gov/pubmed/26490659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1751-6
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge